Meeder Asset Management Inc Geron Corp Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$1.19 - $1.65 $671 - $930	-564 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$0.99 - $1.6 $558 - $902	564 New	564 $1,000
Q4 2021 Feb 11, 2022	SELL	$1.22 - $1.72 $383 - $540	-314 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$1.2 - $1.5 $1 - $1	-1 Reduced 0.32%	314 $0
Q1 2021 Apr 28, 2021	BUY	$1.52 - $2.1 $478 - $661	315 New	315 $0
Q4 2020 Feb 09, 2021	SELL	$1.55 - $2.05 $1,839 - $2,433	-1,187 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$1.05 - $2.18 $25 - $52	-24 Reduced 1.98%	1,187 $3,000
Q1 2020 May 15, 2020	BUY	$0.89 - $1.49 $1,077 - $1,804	1,211 New	1,211 $1,000
Q2 2019 Aug 05, 2019	SELL	$1.37 - $2.02 $2,938 - $4,332	-2,145 Closed	0 $0
Q1 2019 Apr 16, 2019	BUY	$1.01 - $1.83 $852 - $1,544	844 Added 64.87%	2,145 $4,000
Q4 2018 Jan 17, 2019	SELL	$0.98 - $1.85 $3,036 - $5,731	-3,098 Reduced 70.43%	1,301 $1,000
Q3 2018 Nov 02, 2018	BUY	$1.76 - $6.38 $3,190 - $11,566	1,813 Added 70.11%	4,399 $0
Q2 2018 Jul 24, 2018	BUY	$3.29 - $4.82 $8,507 - $12,464	2,586 New	2,586 $0

306

465M

1.07M

648K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $635M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.